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Abstract
Aims/hypothesis. The aim of this study was to develop
a simulation model for Type 2 diabetes that can be
used to estimate the likely occurrence of major diabe-
tes-related complications over a lifetime, in order to
calculate health economic outcomes such as quality-
adjusted life expectancy.
Methods. Equations for forecasting the occurrence of
seven diabetes-related complications and death were esti-
mated using data on 3642 patients from the United King-
dom Prospective Diabetes Study (UKPDS). After exam-
ining the internal validity, the UKPDS Outcomes Model
was used to simulate the mean difference in expected
quality-adjusted life years between the UKPDS regimens
of intensive and conventional blood glucose control.
Results. The model’s forecasts fell within the 95%
confidence interval for the occurrence of observed
events during the UKPDS follow-up period. When the
model was used to simulate event history over pa-
tients’ lifetimes, those treated with a regimen of con-
ventional glucose control could expect 16.35 undis-
counted quality-adjusted life years, and those receiv-
ing treatment with intensive glucose control could ex-
pect 16.62 quality-adjusted life years, a difference of
0.27 (95% CI: −0.48 to 1.03).
Conclusions/interpretations. The UKPDS Outcomes
Model is able to simulate event histories that closely
match observed outcomes in the UKPDS and that can
be extrapolated over patients’ lifetimes. Its validity in
estimating outcomes in other groups of patients, how-
ever, remains to be evaluated. The model allows simu-
lation of a range of long-term outcomes, which should
assist in informing future economic evaluations of in-
terventions in Type 2 diabetes.
Keywords Blood glucose · Diabetes · Diabetes-related
complications · Economic evaluation · Life 
expectancy · Quality-adjusted life years · Risk 
equation simulation model · UKPDS
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Introduction
Computer simulation models are being used increas-
ingly both to model the progression of Type 2 diabetes
and to estimate lifetime outcomes associated with dif-
ferent disease management strategies. These models
estimate the future occurrence of diabetes-related
complications and quantify outcomes in terms of
mean life expectancy or mean quality-adjusted life ex-
pectancy. They can also be used to estimate future
healthcare costs of patients with Type 2 diabetes, but
their main purpose is to estimate the cost-effective-
ness of different disease management strategies, espe-
cially when evidence of the impact of interventions on
surrogate endpoints is limited, or where evidence from
clinical trials has to be extrapolated over patients’ life-
times. Currently, there are at least five simulation
models being used in these ways [1, 2, 3, 4, 5].
Existing simulation models have synthesised data
from a variety of sources into a series of modules that
are used to estimate occurrence of different complica-
tions. For example, the first model of the progression
of Type 2 diabetes had separate modules for cardio-
vascular disease, retinopathy, nephropathy and neu-
ropathy [1], and used a probabilistic Monte-Carlo
analysis to simulate event histories over the remaining
lifetimes of newly diagnosed patients with Type 2 dia-
betes. While that model represented a landmark in the
use of computer simulation to model the progression
of the disease, it had several limitations. In particular,
it placed considerable reliance on data from a Type 1
diabetes trial [6] and on cardiovascular risk estimates
derived from the Framingham cohort study, despite
there being only 337 people with Type 2 diabetes in
the Framingham study and consequent doubts con-
cerning its predictive accuracy for such patients [7].
The Framingham cardiovascular risk equations for the
general population were modified by a dichotomous
variable indicating the presence or absence of diabe-
tes. It was also unable to simulate the timing or occur-
rence of multiple complications and hence could not
fully capture the clustering of complications that tend
to arise [2]. While subsequent simulation models have
been able to address some of these limitations [2],
there is a need for a comprehensive integrated system
of equations from a large and well-validated diabetes-
specific data source to forecast major diabetes-related
complications.
Observational analyses using data from the
UKPDS have examined the relationship between ex-
posure to glycaemia [8] and levels of systolic BP [9]
over time, and the development of macrovascular and
microvascular complications. The results of these
studies, expressed in terms of the change in relative
risk of major complications associated with decre-
ments in HbA1c or systolic BP, were consistent with
those obtained with regimens of intensive control of
blood glucose and BP in the clinical trial. The UKPDS
Risk Engine, a risk calculator for estimating absolute
risk of coronary heart disease [10] and stroke [11], has
been developed based on factors such as age, sex,
race, smoking status, and levels of HbA1c, systolic BP
and lipid ratios in the first 2 years after diagnosis of
Type 2 diabetes.
The model presented here, called the UKPDS Out-
comes Model, develops further the modelling of life-
time outcomes, through a system of equations, to pre-
dict the occurrence and timing of seven diabetes-relat-
ed complications and death, and thereby to calculate
life expectancy and quality-adjusted life expectancy
for patients with Type 2 diabetes. A key aspect of this
model is that it is designed to capture the association
between different types of complications at an individ-
ual patient level. Complications may be associated not
only because they share common known risk factors,
but also due to the event-related dependence that aris-
es when one complication substantially increases the
likelihood of another [2]. For example, the probability
of a patient experiencing congestive heart failure
(CHF) or myocardial infarction (MI) is positively as-
sociated with systolic BP, but the risk of an MI is
higher for patients with a history of CHF due to event-
related dependence. To account for these dependen-
cies the model makes use of time-varying risk factors,
which also facilitates its application to patient groups
at different stages of the disease.
Subjects and methods
Study subjects. The UKPDS was a clinical trial evaluating reg-
imens with more intensive control of blood glucose and BP
than had been described previously [12]. Briefly, between
1977 and 1991, 5102 patients with newly diagnosed Type 2 di-
abetes were recruited to the study. The subjects were aged be-
tween 25 and 65 years, were subsequently shown to have a
fasting plasma glucose of above 6 mmol/l on two occasions,
had no recent history of MI, ischaemic heart disease (IHD) or
CHF, and had never had more than one major vascular event or
a severe concurrent illness that would limit life expectancy.
Biochemical measurements were taken, including HbA1c, sys-
tolic BP, and lipid and lipoprotein fractions at entry to the
study, at randomisation after 3 months of dietary therapy, and
in each subsequent year. The systolic BP result was the aver-
age of three measurements taken at the same visit. Lipids were
included in the model as the ratio of total cholesterol : HDL
cholesterol. The methodology for the biochemical measure-
ment of HbA1c in the UKPDS, and standardisation with mea-
sures reported in the DCCT has been reported elsewhere [13].
Included in this analysis were results from 3642 patients
(white, Asian–Indian and Afro-Caribbean) where annual data
on potential risk factors were available. The characteristics of
these patients and comparisons with the 3867 patients included
in the UKPDS glucose control study have been reported else-
where [8].
The study design and protocol amendments, which are in
accordance with the guidelines of the Declaration of Helsinki
as revised in 2000, were approved by the Central Oxford Re-
search Ethics Committee and by the equivalent committees at
each centre. Each patient also gave informed witnessed con-
sent.
Model structure. The aim of the UKPDS Outcomes Model is to
estimate the first occurrence of each of seven diabetes-related
complications (fatal or non-fatal MI, other IHD, stroke, heart
failure, amputation, renal failure and eye disease measured in
terms of blindness in one eye) and death in order to estimate
lifetime outcomes and quality-adjusted life expectancy. The
model is based on an integrated system of parametric equations
used to estimate absolute risk of any of the above complica-
tions based on the patient’s characteristics (e.g. age and sex),
and time-varying risk factors such as HbA1c and the patient’s
history of complications. Definitions of all risk factors initially
included in the model are listed in Table 1. To improve model
stability, values for time-varying risk factors (HbA1c, systolic
BP, and total cholesterol : HDL cholesterol) were calculated as
the means of the values for the previous 2 years (e.g. the value
for these variables in the fourth year was the average of the
values from the second and third years), while smoking status
was based on 3-year periods from diagnosis of diabetes. To
model the long-term dependence [14] between different com-
plications, time-varying covariates indicating whether a patient
had had a history of other complications since diagnosis of dia-
betes were also included in the model. These covariates were
set to 0 until an event occurred, and then set to 1 from that
point onwards.
The procedures used to fit equations to the observed events
in the UKPDS population, as well as the estimated parameters,
are reported in greater detail in the statistical appendix. In
brief, each type of diabetes-related event was modelled using
one or more equations that included time-varying risk factors.
In the case of diabetes-related complications, a Weibull pro-
portional hazards regression was used to model the occurrence
of a composite outcome covering both fatal and non-fatal
events. The coefficients for risk factors were then estimated
using maximum likelihood methods that account for censoring
(e.g. due to factors such as loss of follow-up, or death). Risk
factors with a p value of less than 0.05 were considered statis-
tically significant. Separate equations were used to model dia-
betes- and non-diabetes-related mortality using a combination
of Gompertz and logistic regression equations. Finally, the
time paths of four risk factors were also estimated using these
data. To aid exposition, we grouped the estimated equations
into the following categories.
Cardiovascular disease. The increased risk of cardiovascular
disease among people with Type 2 diabetes is well established
and is increasingly recognised as one of the major hazards of
Type 2 diabetes. In developed countries, cardiovascular disease
accounts for the majority of deaths amongst patients with Type
2 diabetes [15] and is a significant contributor to diabetes-relat-
ed healthcare costs [16]. Within the cardiovascular disease cate-
gory we have three Weibull equations to estimate the absolute
risk of the following: (i) MI, defined as non-fatal myocardial
infarction (International Classification of Diseases, Ninth Revi-
sion [ICD-9] code 410), or fatal vascular cardiac event (ICD-9
codes ≥410–≤414.9, or ≥428–≤428.9), or sudden death (ICD-9
codes ≥798–≤798.9); (ii) IHD, defined as an ICD-9 code of
≥411–≤414.9; and (iii) CHF, defined as an ICD-9 code of
≥428–≤428.9. We only recorded IHD and CHF events if they
occurred prior to an MI event; a patient who had experienced
an MI was not classified subsequently as developing IHD.
Cerebrovascular disease. People with Type 2 diabetes have a
higher risk of stroke, and previous epidemiological studies
Table 1. Abbreviations, definitions and values of variables included in the model
Abbreviations Definitions/values Transformation applied
AGE Age in years at diagnosis of diabetes AGE—52.59
AGE_EVENT Age in years at occurrence of first diabetes-related event elevating AGE_EVENT—52.59
risk of mortality 
YEAR Time since diagnosis of diabetes (years)
YEAR 2 1 if year = 2; 0 otherwise 
FEMALE 1 for female; 0 for male
AC 1 Afro-Caribbean; 0 for Caucasian or Asian Indian
SMOK 1 for current smoker, of tobacco in any form; 0 otherwise
SMOK_BASE 1 for smoker of tobacco in any form after diagnosis of diabetes; 
0 otherwise
BMI Body mass index at diagnosis of diabetes (m/kg2) BMI—27.77
HBA1C HbA1c (%), 2-year moving average of yearly values HBA1C—7.09
LHBA1C HbA1c (%), lagged 1 year LHBA1C—7.09
HBA1C_BASE HbA1c (%), after diagnosis of diabetes HBA1C_BASE—7.09
SBP Systolic BP (mm Hg), 2-year moving average of yearly values (SBP—135.09) / 10
LSBP Systolic BP (mm Hg), lagged 1 year values (LSBP—135.09) / 10
SBP_BASE Systolic BP (mm Hg), after diagnosis of diabetes (SBP_BASE—135.09) / 10
TOTAL:HDL Total cholesterol : HDL cholesterol ratio, 2-year moving average TOTAL:HDL—5.23
of yearly values
LTOTAL:HDL Total cholesterol : HDL cholesterol ratio, lagged 1 year values. LTOTAL:HDL—5.23
LTOT:HDL_BASE Total cholesterol : HDL cholesterol ratio, after diagnosis of diabetes LTOT:HDL_BASE—5.23
ATRFIB 1 for atrial fibrillation at diagnosis of diabetes; 0 otherwise
PVD 1 for peripheral vascular disease at diagnosis of diabetes; 0 otherwise
IHD 1 for history of IHD; 0 otherwise
MI_EVENT 1 for year of first MI event; 0 otherwise
MI_POST 1 for all years after first MI event; 0 otherwise
STROKE_EVENT 1 for year of first stroke event; 0 otherwise
CHF 1 for history of congestive heart failure; 0 otherwise
AMP 1 for history of amputation; 0 otherwise
BLIND 1 for history of blindness in one eye; 0 otherwise
RENAL 1 for history of renal failure; 0 otherwise
have found that this risk increases with age, elevated BP,
smoking and lipoprotein levels [17]. In our model a single
Weibull equation was used to estimate the absolute risk of a
first non-fatal stroke (ICD-9 codes ≥430–≤434.9, or 436) or fa-
tal stroke (ICD-9 codes ≥430–≤438.9).
Amputation. Patients with diabetes have an amputation rate
that is many times higher than that of patients without diabe-
tes, and previous studies have found that the primary risk fac-
tors for amputation include age, (male) sex, smoking, the pres-
ence of peripheral vascular disease, and BP [18]. Our model
contains a single Weibull equation to estimate the absolute risk
of a first amputation of a digit or limb (ICD-9 codes
≥5.845–≤5.848, or 250.6) or a fatal peripheral vascular event
(ICD-9 codes 997.2, 997.6, 250.6 or 440.2).
Blindness. The model contains a Weibull equation to estimate
the risk of blindness in one eye, which is defined as a visual
acuity Snellen 6/60 or ETDRS logMAR 1.0 or worse for any
reason, persisting for 3 months (ICD-9 codes ≥369–≤369.9).
Nephropathy. Increasing duration of diabetes, hypertension and
poor glycaemic control have been shown to elevate the risk of
renal disease [19] and the subsequent risk of mortality [20].
Our model contains a single Weibull equation to predict renal
failure, defined as creatinine levels of above 250 µmol/l, not
ascribable to any acute inter-current illness (ICD-9 codes
250.3, and ≥585–≤586), and death due to renal failure (ICD-9
codes ≥580–≤593.9).
Risk factor progression. Previous simulation models of the
progression of diabetes have made a variety of assumptions re-
garding how risk factors such as HbA1c and systolic BP
change over time [2, 4]. While carrying forward current values
provides a simple means of extrapolation [21, 22], it does not
account for the likely change in some of these risk factors over
time (e.g. the upward trend in HbA1c levels that many patients
experience). In the UKPDS Outcomes Model, we treat the four
risk factors (HbA1c, systolic BP, total cholesterol : HDL cho-
lesterol, and smoking status) as panel data (longitudinal data),
and fit a random effects model to allow estimation of a time
path [23]. While the exact specification differs between risk
factors, these equations generally include the value or status of
the risk factor at the time a decision was made regarding ran-
domisation in the UKPDS (which took place after a 3-month
dietary run-in) [24], the number of years since diagnosis, and
the value of the risk factor in the preceding period. For HbA1c
an indicator variable for the second year was also included to
account for the initial decline in HbA1c observed in the study.
Equations for HbA1c, systolic BP, and total cholesterol : HDL
cholesterol were based on annual measures of each risk factor,
while smoking status (due to its less frequent ascertainment)
was based on 3-year periods from diagnosis of diabetes.
Mortality. People diagnosed with Type 2 diabetes in middle
age typically have a life expectancy of between 5 and 10 years
shorter than people without diabetes, with heart disease being
the major underlying cause of death [25]. Our model contains
three equations for estimating absolute risk of mortality. Two
of these equations estimate the likelihood of death after the oc-
currence of several diabetes-related complications that have
been shown to elevate the risk of mortality. The first equation,
based on logistic regression, estimates the probability of death
in the first year in which either an MI, CHF, stroke, amputation
or renal failure first occurs (as defined in the Weibull models
outlined above). The second equation estimates the risk of dia-
betes-related mortality of patients with a history of any of
these events in all subsequent years. The third mortality equa-
tion estimates the risk of death from causes unrelated to diabe-
tes (primarily due to cancers and accidents).
Using the model to simulate outcomes. The main purpose of
the model is to estimate the likely occurrence of the major dia-
betes-related complications over a lifetime for patients with
specified prognostic risk factors, in order to calculate health
outcomes such as life expectancy or quality-adjusted life ex-
pectancy.
While increases in mean life expectancy are widely recog-
nised as a useful measure of benefit [26], it is also important to
encapsulate the potential impact of complications on quality of
life. This model uses the quality-adjusted life-years (QALY)
method to adjust length of life for quality of life by assigning a
value or health utility, on a scale on which 0 represents death
and 1 represents full health, for each year of life.
The impact on utility of different diabetes-related complica-
tions has been reported in a number of studies, including one
study in which the EQ-5D health status questionnaire [27] was
used to survey 3192 patients still participating in the UKPDS
in 1997 [28]. Based on data from that survey, the mean utility
for patients free of microvascular and macrovascular complica-
tions was estimated at 0.78. Patients with a history of compli-
cations have a lower utility and the following decrements were
estimated: −0.055 for an MI; −0.090 for other IHD; −0.164 for
stroke; −0.108 for heart failure; −0.280 for amputation; and −
0.074 for blindness in one eye. For simplicity and in the ab-
sence of sufficient data to estimate empirically, it is assumed
that multiple complications have an additive effect on utility,
e.g. the utility of a patient who had other IHD and then had an
MI would first be decremented by 0.090 and then by a further
0.055. However, the UKPDS Outcomes Model is sufficiently
flexible to allow other assumptions to be adopted regarding the
impact that different complications (and combinations of com-
plications) have on quality of life.
When estimating QALYs it is important to model the se-
quence of endpoints for each patient. For example, consider
the simulated profiles for two patients who are free of compli-
cations: the first patient is predicted to have an amputation in
the second year post follow-up, an IHD and an MI in the fourth
year post follow-up, and is predicted to die in the fifth year;
the second patient is predicted to have IHD in the third year
post follow-up, an amputation in the fourth year, and a fatal MI
in the fifth year. Using the utility weights reported above,
while both patients experience the same set of diabetes-related
complications over their remaining lifetimes, the QALY profile
is different: the profile of the first patient is equivalent to 2.19
QALYs, and the second is equivalent to 2.66 QALYs. By sim-
ulating individual patient histories, the model is able to take
these differences into account.
Simulations are based on a probabilistic discrete-time ill-
ness–death model [14] with annual cycles. In the model, pa-
tients start with a given health status (e.g. no complications)
and can have one or more non-fatal complications and/or can
die in any model cycle. Figure 1 provides an algorithm that il-
lustrates the sequence of modelling events. To begin, the val-
ues for all the characteristics for each patient included in the
simulation are set (the variables representing these characteris-
tics are listed in Table 1). The first cycle of the model is then
run, in which the probability of death or of experiencing the
seven complications is calculated. Each probability is com-
pared with a random number drawn from a uniform distribu-
tion ranging from 0 to 1 to determine whether an event occurs.
There is a need to account for event-related dependence be-
tween some complications, as noted above. The actual event-
related dependencies were estimated empirically during the
equation-fitting procedure, and included if they had a signifi-
cance level (p value) of less than 0.05. We then checked all
significant dependencies against the known epidemiology, as
discussed in more detail below. In the model, if a non-fatal
event is predicted to have occurred, the patient acquires a his-
tory of that event (the time-varying covariate for that endpoint
is updated from 0 to 1), and thereafter carries that history in
their set of characteristics. In addition, as noted above, the two
diabetes-related mortality equations are applied to all patients
who have a history of complications that were found to elevate
the risk of death (MI, CHF, stroke, amputation or renal failure)
from the point at which the complication is predicted to have
occurred. These equations deal with the likelihood of immedi-
ate death following the first event, and the long-term elevation
of risk of death consequent to acquiring a history of these com-
plications. Finally a non-diabetes mortality equation is used to
forecast the incidence of death from cancer, accidents or other
causes not addressed elsewhere in the model.
If the model predicts that a death has occurred, the years
lived and quality-adjusted years lived (life years decremented
in each cycle by the reduced quality of life associated with par-
ticular complications) by that patient are calculated. If the pa-
tient is predicted to have survived that cycle, the risk factor
equations are used to update their current risk factor values
(e.g. systolic BP) and these are carried forward to the next cy-
cle of the model along with the updated event history.
It is important to note that the order in which the event
equations listed in Figure 1 (equations 1 to 10) are evaluated to
determine the occurrence of an event is not predetermined.
Further, some of these events are competing risks (e.g. if a pa-
tient dies within a cycle of the model, they can have no addi-
tional events). To take this into account, the equations are run
in random order in each cycle.
Internal validation of the model using the UKPDS population.
We tested the consistency of the forecast cumulative incidence
of different complications and death to the cumulative inci-
dence calculated using non-parametric (life-table) methods.
This test of internal validity [29] was based on the forecast
number of events from the second to the twelfth year after di-
agnosis, using the information from the first year after diagno-
sis in the 3642 patients used to estimate the model [11].
Application of the model. We demonstrate two potential appli-
cations of the model. Firstly, we used the simulation model to
extrapolate outcomes over the remaining lifetime of the 3867
patients randomised to conventional or intensive blood glucose
control in the UKPDS. Estimated outcomes are stratified by
sex and 5-year age categories for patients over 45 years of age
at diagnosis of diabetes. Secondly, we calculated the incremen-
tal benefit of a regimen of intensive blood glucose control
compared with conventional therapy for patients’ remaining
lifetimes in terms of life expectancy and quality-adjusted life
expectancy. Previously, in the absence of a full outcomes mod-
el, we reported the cost-effectiveness of this intervention only
in terms of time free of diabetes-related complications [30] us-
ing all patients randomised in that comparison rather than the
3642 used here. Given the illustrative nature of these applica-
tions we did not discount outcomes.
Handling uncertainty. Appropriate handling of uncertainty in
complex patient simulation models such as the UKPDS Out-
Fig. 1. Algorithm for model
simulation
comes Model is not straightforward. In applications involving
extrapolation of outcomes of patients who were alive at the
end of the study, a combination of bootstrap methods and mul-
tiple imputation methods were used. The confidence intervals
around the QALY estimates were adjusted to take into account
the variance within and across imputed data sets [31]. Our
method removes Monte-Carlo error, so that confidence inter-
vals from the outcomes model reflect parameter uncertainty in
the model.
Results
The median follow-up time of patients in the UKPDS
was 10.3 years with 39 460 person-years of follow-up
data available for model fitting. The coefficients rep-
resenting the log of the hazard ratios (or the log of the
odds ratio in the case of the logistic equations repre-
senting event fatality [equation 8] and smoking status
[equation 14]), and the standard errors for each coeffi-
cient are listed in Table 2 (event equations), Table 3
(mortality equations) and Table 4 (risk factor equa-
tions). The numbers of subjects in which each equa-
tion was estimated are also shown. In three event
equations (IHD, CHF and stroke), a small number of
patients with missing information were omitted from
that particular estimation, but the eliminated cases re-
present less than 1% of the total.
The relationship between the equations is illustrat-
ed in Figure 2 along with the estimated hazard or odds
ratio for each risk factor. When interpreting these ra-
tios it is important to note that some of the risk factors
have been subject to a log transformation. The arrows
in the figure linking different equations indicate the
existence and the direction of event-related depen-
dence, e.g. the arrow from CHF to MI indicates that
an individual who has experienced CHF subsequently
has a 4.74-fold increased risk of MI.
Respectively for the risk factors HbA1c, systolic BP,
total cholesterol : HDL cholesterol and smoking status,
Figure 3a–d shows: (i) the actual mean value of the
risk factor (for the 3642 patients used to estimate the
model); (ii) the predicted values, using the equations
given in Table 4, for patients with differing values of
the relevant risk factor at the time of the decision re-
garding randomisation in the UKPDS. For HbA1c,
which is shown in Figure 3a, it is evident that patients
with an initial value of between 6% and 8% subse-
quently follow a time path similar to the mean of the
observed values for all patients, while the time path for
patients with higher initial values differs from the
mean of the observed values for all patients, possibly
reflecting more intensive treatment aimed at improving
the metabolic control of these high-risk patients.
Figure 4 shows the simulated and actual cumulative
incidence for each of the diabetes-related events, and
all-cause mortality up to 12 years from diagnosis. The
estimated number of patients experiencing each event
is initially based on baseline levels of risk factors and
hence on the time paths predicted by the time-varying
risk factor equations. The predicted numbers in all
cases are within the 95% confidence intervals sur-
rounding the actual cumulative incidence curves for
the study population.
Two illustrative applications of the model. Estimates
of mean life expectancy and mean quality-adjusted
Table 2. Sample size, functional form, parameters and beta coefficients (SEs) for seven equations to estimate the probability of diabetes-
related complications
Eq. 1 Eq. 2 Eq. 3 Eq. 4 Eq. 5 Eq. 6 Eq. 7
Complication IHD MI CHF STROKE AMP BLIND RENAL
No. of subjects 3612 3642 3607 3607 3642 3642 3642
Functional form Weibull Weibull Weibull Weibull Weibull Weibull Weibull
Parameters Estimate of coefficient (SE)
λ −5.310 (0.174) −4.977 (0.160) −8.018 (0.408) −7.163 (0.342) −8.718 (0.613) −6.464 (0.326) −10.016 (0.939)
ρ 1.150 (0.067) 1.257 (0.060) 1.711 (0.158) 1.497 (0.126) 1.451 (0.232) 1.154 (0.121) 1.865 (0.387)
AGE 0.031 (0.008) 0.055 (0.006) 0.093 (0.016) 0.085 (0.014) 0.069 (0.014)
FEMALE −0.471 (0.143) −0.826 (0.103) −0.516 (0.171)
AC −1.312 (0.341)
SMOK 0.346 (0.097) 0.355 (0.179)
BMI 0.066 (0.017)
HBA1C 0.125 (0.035) 0.118 (0.025) 0.157 (0.057) 0.128 (0.042) 0.435 (0.066) 0.221 (0.050)
SBP 0.098 (0.037) 0.101 (0.026) 0.114 (0.056) 0.276 (0.042) 0.228 (0.075) 0.404 (0.106)
TOTAL:HDL 0.113 (0.025)
Ln (TOTAL:HDL) 1.498 (0.202) 1.190 (0.169)
PVD 2.436 (0.521)
ATRFIB 1.428 (0.472)
IHD 0.914 (0.150)
CHF 1.558 (0.202) 1.742 (0.287)
BLIND 1.812 (0.462) 2.082 (0.551)
life expectancy by age group and sex are listed in Ta-
ble 5. For example, the mean life expectancy for
males between the age of 45 and 50 years at diagnosis
of diabetes is 25.54 years (95% CI: 21.92–29.66).
This compares with 30.05 years remaining life expect-
ancy for males between the age of 45 and 50 years in
the UK general population in 1999 to 2001 [32], sug-
gesting a loss of approximately 5 years of life at-
tributable to Type 2 diabetes, in line with previously
reported estimates [25]. The corresponding mean
quality-adjusted life expectancy is estimated to be
18.82 (95% CI: 16.48–21.15) QALYs. As in the gen-
eral population, women have a higher life expectancy
at all ages. It is important to note that life expectancies
are for cohorts in the UKPDS, and given the criteria
for inclusion in the study (e.g. no recent history of
Table 3. Sample size, functional form, parameters and beta coefficients (SEs) for three equations to estimate the probability of
mortality
Eq. 8 Eq. 9 Eq. 10
Event EVENT FATALITYa DIABETES MORTALITYa OTHER DEATH
No. of subjects 717 584 3642
Functional form Logistic Gompertz Gompertz
Parameters Estimate of coefficient (SE)
λ −3.251 (0.358) −5.124 (0.363) −6.373 (0.162)
φ 0.003 (0.038) 0.154 (0.016)
Ln (AGE_EVENT) 2.772 (0.716) 4.731 (1.066)
AGE × (FEMALE) 0.081 (0.013)
AGE × (1-FEMALE) 0.104 (0.012)
SMOK 0.307 (0.141)
HBA1C 0.114 (0.053)
TOTAL:HDL 0.109 (0.047)
MI_EVENT 2.640 (0.336) 3.939 (0.275)
MI_POST 1.119 (0.277)
STROKE_EVENT 1.048 (0.376) 2.807 (0.408)
RENAL 1.585 (0.315)
AMP 1.032 (0.377)
a Regression estimates based on the patients who experienced one or more of the following complications: MI, CHF, stroke, ampu-
tation, renal failure
Table 4. Sample size, functional form, parameters and beta coefficients (SEs) for four equations used to estimate annual risk factor
values from diagnosis of diabetes
Eq. 11 Eq. 12 Eq. 13 Eq. 14
Risk factor HBA1C SBP TOTAL:HDL SMOK
No. of subjects 3631 3592 3520 3536
Type of regression Panel Panel Panel Logistic
r2 0.64 0.65 0.44
Parameters Estimate of coefficient (SE)
α −0.024 (0.017) 0.030 (0.014) −0.021 (0.007) −4.020 (0.236)
Ln (YEAR) 0.144 (0.009) 0.039 (0.008)
YEAR −0.203 (0.024)
YEAR_2 −0.333 (0.050)
AGE −0.027 (0.008)
FEMALE −0.489 (0.154)
LHBA1C 0.759 (0.004)
HBA1C_BASE 0.085 (0.004)
LSBP 0.717 (0.004)
SBP_BASE 0.127 (0.004)
LTOTAL:HDL 0.526 (0.005)
LTOTAL:HDL_BASE 0.252 (0.006)
LSMOK 1.878 (0.211)
SMOK_BASE 4.879 (0.494)
Fig. 2. Summary of model
equations showing event-re-
lated dependencies and haz-
ard/odds ratio for each risk
factor. The hazard/odds ratio
shown for each risk factor is
the exponent of the beta co-
efficients shown in Tables 2
and 3
Fig. 3. Legend see page 1755
MI), these patients may have longer life expectancies
than some diabetic cohorts in the general population.
Further, reported confidence intervals are for the life
expectancies of cohorts, and the estimated life expect-
ancy for any individual patient would be subject to a
much greater level of uncertainty.
Table 6 reports the quality-adjusted life expectancy
for UKPDS patients who were treated with a regimen
of intensive and conventional blood glucose control
under the trial protocol. The quality-adjusted life ex-
pectancy for the conventional group was 16.35
QALYs, and that for the intensive group was 16.62
QALYs, a difference of 0.27 (95% CI: −0.48 to 1.03)
QALYs. Such estimates will permit the calculation of
cost-effectiveness.
Discussion
Simulation models such as the UKPDS Outcomes
Model make it possible to quantify the lifetime impact
of chronic diseases and the long-term benefits associ-
ated with alternative management strategies. They are
therefore an important adjunct to randomised con-
trolled trials and other types of epidemiological study,
and may also be of value in disease management and
healthcare planning. They are essential for proper
evaluation of interventions affecting any of the risk
factors incorporated in the model, because they permit
users to estimate the likely occurrence, over a lifetime,
of the main diabetes-related complications. Only
when this has been done can quality-adjusted life ex-
pectancy and lifetime treatment costs be fully estimat-
ed, and the cost-effectiveness of the intervention cal-
culated.
As noted in the Introduction, a number of other dia-
betes simulation models have been developed, and the
present model has benefited greatly from the insights
these have provided.
The UKPDS Outcomes Model has some important
advantages over some previous simulation models: (i)
we used data from 3642 patients who participated in
the UKPDS; (ii) there was a median follow-up period
of 10.3 years; (iii) we analysed full clinical histories
including biochemical measures and ascertainment of
major diabetes-related complications; and (iv) there
was a very low loss of data during follow-up. The
quantity and quality of these data, and the fact that
they have come from a single study, has obviated the
need to synthesise evidence from many disparate
sources. Indeed, we have also been able to use this pa-
tient population to estimate the impact of the same di-
abetes-related complications on subsequent healthcare
costs and on quality of life. These results have been
Fig. 3. Observed and simulated time paths for (a) mean
HbA1c, (b) systolic BP and (c) total cholesterol : HDL choles-
terol, from diagnosis of diabetes, as well as for (d) smoking
status
Table 5. Estimated mean life expectancy and mean quality-adjusted life expectancy by age at diagnosis of diabetes in the UKPDS
populationa
Life expectancy (95% CI [years]) Quality-adjusted life expectancy (95% CI [QALYs])
Age at diagnosis Men Women Men Women
of diabetes
45–49 25.54 (21.92–29.16) 26.80 (22.12–31.48) 18.82 (16.48–21.15) 20.06 (16.92–23.19)
50–54 21.51 (18.65–24.37) 23.58 (19.94–27.22) 15.96 (14.14–17.79) 17.62 (15.30–19.93)
55–59 17.94 (15.78–20.11) 20.16 (17.34–22.98) 13.34 (11.97–14.71) 15.10 (13.23–16.97)
60–64 13.91 (12.55–15.27) 17.65 (16.58–19.73) 10.34 (9.46–11.22) 13.15 (11.88–14.42)
a Based on 3405 patients between 45 and 65 years randomised to regimens of intensive or conventional blood glucose control
Table 6. Estimated life ex-
pectancy and QALYS for
UKPDS patients on conven-
tional and intensive blood
glucose control
UKPDS regimen
Conventional group Intensive group Difference (95% CI)
Life expectancy
Within trial 9.88 10.00 0.12 (−0.13 to 0.36)
Over lifetime 21.98 22.35 0.37 (−0.72 to 1.46)
Quality-adjusted life expectancy
Within trial 7.62 7.72 0.10 (−0.09 to 0.29)
Over lifetime 16.35 16.62 0.27 (−0.48 to 1.03)
Fig. 4. Legend see page 1757 
reported elsewhere [28] but in time will be integrated
with the outcome model described here to form part of
a more general UKPDS diabetes health economics
model.
The volume of data available to us also removed
many constraints on the modelling approach adopted
and allowed us to construct a model based on a set of
equations estimated using a consistent methodology.
In particular, our use of time-varying covariates al-
lowed us to model the linkages between different dia-
betes-related complications. These have increasingly
been recognised as crucial to such simulation models:
as a recent study has noted “...it can be catastrophical-
ly inaccurate to simulate each kind of event as if it
were statistically independent” [2]. We have attempted
to address this issue by incorporating linkages where
there is a high degree of statistical significance and
supporting clinical and epidemiological evidence. For
example, our results for stroke are consistent with
those from the Framingham study showing that a his-
tory of heart failure and atrial fibrillation increase the
risk of subsequent stroke [17]. The model may also be
used to simulate outcomes in populations with differ-
ing baseline characteristics such as age, smoking sta-
tus, systolic BP, blood lipids, HbA1c and history of di-
abetes-related complications.
A number of limitations of the UKPDS Outcomes
Model should be acknowledged. Firstly, the model
only predicts the first event in any single category of
diabetes-related complications, and does not allow se-
ries of events such as sequential amputations to be
modelled directly. However, this limitation should not
be overstated, as: (i) such multiple events in the
UKPDS data were relatively infrequent; (ii) subse-
quent fatal events in specific categories of diabetes-re-
lated complications are included in the diabetes-relat-
ed mortality equation; and (iii) additional post-study
monitoring data will in time allow this issue to be re-
visited.
Secondly, the model does not explicitly incorporate
a number of morbidities related to diabetes. In particu-
lar, peripheral neuropathy and ulceration may give
rise to significant reduction in quality of life, to hospi-
talisation and to high treatment costs [33]. These con-
ditions are also likely to elevate the risk of subsequent
events such as amputation. However, these were not
included as major endpoints in the UKPDS and cannot
easily be incorporated into the outcomes model. Hy-
poglycaemia and hyperglycaemia are also excluded.
Episodes of these conditions are infrequent and rarely
serious, but more serious morbidity could occur in
small numbers of patients undertaking intensive gly-
caemic management.
Thirdly, some complications of diabetes are repre-
sented in the model using a single state. For example,
the only state representing eye disease in the model is
the endpoint of blindness in one eye. Again, this is
consistent with the primary analyses of the UKPDS,
but it almost certainly fails to fully describe the com-
plex process of disease progression and associated
treatments, as well as the potential impact on quality
of life. There is scope to develop a more detailed
model of the progression of eye disease in future
work.
Fourthly, we have briefly described the methods
used to estimate confidence intervals around our esti-
mates, but there are many important methodological
and computational issues in the generation of these
confidence intervals and more generally in the ways
uncertainty should be handled in a complex model;
these need to be explored in greater detail in the fu-
ture.
We expect the UKPDS Outcomes Model to develop
in a number of ways as further follow-up data become
available. The greater length of follow-up will allow
the shape of the hazard in the Weibull and Gompertz
equations to be estimated with greater precision. The
risk factors and linkages contained in the model can
be re-examined, especially the equations that are cur-
rently based on a relatively small number of events
(e.g. only 24 patients had renal failure).
The UKPDS Outcomes Model has been described
here in some detail to demonstrate the rationale for
our approach, the problems encountered and the re-
maining limitations. Publication of the coefficients of
all equations and the description of the simulation al-
gorithm have been included to facilitate a high degree
of transparency and to promote a deeper understand-
ing of the model. In this study we have demonstrated
that the UKPDS Outcomes Model is able to simulate
event histories that closely match observed outcomes
of patients in the UKPDS study, and that it can also be
used to extrapolate lifetime outcomes. The next chal-
lenge is to test external validity by applying the model
to other populations of Type 2 diabetic patients. Until
this has been undertaken, caution should be exercised
when using the model to predict outcomes in these
populations. We look forward to the assessment of the
model’s external validity and to its future use in as-
sessing outcomes of therapies for Type 2 diabetes.
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Appendix: Statistical analysis
Details of the statistical modelling. Parametric meth-
ods for risk estimation have previously been applied
in modelling events such as MI and stroke [34, 35,
36]. In this analysis, a proportional hazards Weibull
regression model was used to model diabetes-related
complications with a baseline hazard of the form:
where γ is a shape parameter and the scale parameter
λ=exp(β0) or the exponentiated intercept coefficient
β0. Under the proportional hazards assumption, the
hazard of an event at time t for the ith individual is:
where xtj is a vector of j covariates and βj their respec-
tive coefficients. Some of these covariates (such as
AGE and SEX) remain constant as time elapses; oth-
ers potentially vary over time (such as HbA1c and sys-
tolic BP). Thus, the unknown parameters requiring es-
timation are λ, γ, β0 and βj.
Two types of risk estimation were used to model
the risk of diabetes-related death. Firstly, logistic re-
gression was used to estimate the probability that the
first MI, IHD, CHF, amputation or renal failure event
would be fatal. Secondly, a Gompertz regression mod-
el, a functional form widely used to model mortality,
was used to calculate the risk of diabetes-related mor-
tality in subsequent years for patients with a history of
these complications. Non-diabetes-related mortality
was also modelled using Gompertz regression. For
these models the baseline hazard is:
and is therefore as follows in the proportional hazards
model:
and the unknown parameters requiring estimation are
λ, ϕ, β0 and βj. In the case of diabetes-related mortali-
ty the time at risk is from the occurrence of the first
complication that elevates the risk of mortality.
The unconditional probability of an event occurring
between t and t+1 can be calculated using the integrat-
ed hazard. For example, the integrated hazard at time t
is:
and the unconditional probability of an event occur-
ring in the interval t to t+1 is:
Finally, equations representing risk factor progression
were estimated using random effects panel data re-
gression. Equations 10 to 13 were estimated using the
form:
where RFit is the risk factor for the ith patient (i=1..n)
in year t of the study (t=1,...,T) and xitj are explanatory
variables (j=1.. J). Predicted values of RFit were used
in conjunction with the event equations in order to
complete the simulations. The smoking status equa-
tion (equation 14) used a logistic regression panel data
model to estimate the probability of smoking in 3-year
periods from the diagnosis of diabetes.
Methods for handling uncertainty. The results report-
ed in Tables 5 and 6 were based on a simulation model
that predicts outcomes at the individual level. Repre-
senting uncertainty in models of this type is compli-
cated by the need to remove Monte-Carlo error (the
differences between individual simulations that are
due to the play of chance rather than uncertainty in the
parameters).
Confidence intervals presented in this paper are
based on a two-stage process of evaluation. Firstly, the
original data used to fit the risk equations were boot-
strapped and the risk equations refitted and the coeffi-
cients recorded. Repeating this process 20 times gen-
erated a vector of coefficients that represented the pa-
rameter uncertainty in those coefficients, but which
also accounted for the covariance between risk equa-
tions. As we were applying the model to predict life-
time outcomes of UKPDS patients, in the second
stage we treated the predictions as imputations of mis-
sing values (in that we were predicting values that
were not observed) and the 20 sets of results as multi-
ple imputations. Standard methods for combining the
results of multiple imputations were then employed
[31], including a bias correction to adjust for the fact
that a (relatively) small number of multiple imputa-
tions were performed. Further information on the
model including details of software can be obtained
from: http://www.dtu.ox.ac.uk/outcomesmodel.
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